Recent Updates — MEOBF
Mesoblast Limited announced that directors William Burns and Dr. Philip Krause will retire from the Board at the 2026 Annual General Meeting. Mr. Burns, who has served since 2014, is stepping down after twelve years of service. Dr. Krause, a director since 2022 with prior FDA experience, is also retiring. Ms. Jane Bell AM will assume sole Chairmanship of the Nomination and Remuneration Committee. The Board intends to recruit new directors with U.S. and global commercial expertise in biotechnology and pharmaceuticals to support the company's next phase of growth following the successful launch of Ryoncil in the United States. Mesoblast is a global leader in developing allogeneic cellular medicines for inflammatory diseases.
Mesoblast Limited reported a 44% increase in first-quarter net revenues, reaching US$28 million, driven by continued sales momentum for Ryoncil. Net operational cash spend improved by 86% to US$2.1 million compared to the prior year period. The company completed treatment of all patients in the pivotal Phase 3 MSB-DR004 trial for rexlemestrocel-L in chronic low back pain, with results expected next year. Additionally, Mesoblast held a positive meeting with the FDA regarding the planned Biologics License Application for rexlemestrocel-L to prevent gastrointestinal bleeding in heart failure patients. The company holds US$98.5 million in cash and has fully drawn its US$125 million credit facility.
Mesoblast Limited reported a 44% increase in net revenue from sales of its product Ryoncil to US$28 million for the first fiscal quarter ended September 30, compared with US$19 million in the prior year period. Net operational cash spend improved by 85% to US$2.3 million versus US$14.9 million previously. The company cited strong patient adoption across onboarded sites and a robust cash position of US$99 million at quarter-end. Mesobblast operates as a global leader in developing allogeneic cellular medicines for inflammatory diseases.
Mesoblast reported fiscal year 2026 revenues of US$120.3 million, a significant increase from US$17.2 million in the prior year, driven by the first full year of commercialization for its FDA-approved product Ryoncil. Net product sales for Ryoncil reached US$115.2 million, generating approximately US$104 million in gross profit. The company reduced its net operating cash utilization to US$43.8 million and finished with cash reserves of US$102.9 million. Additionally, Mesoblast established a new US$125 million five-year non-dilutive credit facility to replace higher-cost debt and support future growth initiatives. Clinical milestones included completing enrollment in the pivotal Phase 3 trial for rexlemestrocel-L for chronic low back pain and commencing enrollment for Ryoncil in adults with SR-aGvHD. Mesoblast Limited is a global leader in allogeneic cellular medicines for inflammatory diseases.
Mesoblast Limited's Founder and CEO, Dr. Silviu Itescu, exercised 1,885,334 options at a price of A$1.45 per share, making a total payment of A$2,733,734. Following this transaction, Dr. Itescu's total shareholding increased to 80,844,262 ordinary shares. The CEO did not sell any of the newly acquired shares. Mesoblast is a biotechnology company that develops allogeneic cellular medicines for inflammatory diseases.